COA Submits Comments on CMS&#x27; Proposed CAR T-Cell Coverage Decision

Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy

Autologous cell and gene therapies show promise but face barriers such as high costs, limited access, and payer concerns over long-term effectiveness.

Joshua M. Hare, MD, FACC, FAHA, cofounder, chief science officer, and chairman, Longeveron, and professor of medicine, Miller School of Medicine, University of Miami

REGENXBIO’s ABBV-RGX-314 Reduces Need for AntiVEGF Injections After Application in Fellow Eyes of Patients With Wet AMD

Joshua M. Hare, MD, the cofounder and chief science officer of Longeveron, discussed working to show potential benefits in a follow-up phase 3 trial.

Arshad Khanani, MD, the director of clinical research and director of Fellowship at Sierra Eye Associates

Promising Data on Lomecel-B for Alzheimer Disease

The data comes from a phase 2 substudy (NCT03999801) that treated the fellow eyes of patients who had previously been treated with ABBV-RGX-314.

MeiraGTx’s Parkinson Disease Gene Therapy AAV-GAD Improves Motor Scores and Patient-Reported Quality of Life in Sham-Controlled Study

Joshua M. Hare, MD, the cofounder and chief science officer of Longeveron, discussed updated data from the phase 2a CLEAR MIND study.

Using Programmable Genomic Integration to Make Edits Big and Small

For the patients treated at the high dose, an average improvement of 18 points from baseline was observed in UPDRS Part 3 “off” medication score at 26 weeks posttreatment.

John Finn, PhD, the chief scientific officer of Tome Biosciences

John Finn, PhD;Noah Stansfield

Payer Challenges for Patient Access to Autologous Cell and Gene Therapies

John Finn, PhD, the chief scientific officer of Tome Biosciences, discussed the company’s pipeline for its new technology.

Related Content

Molly Borchardt, PharmD;Phil Cyr, MPH;Erin Lopata, PharmD, MPH;Jason Foster, MBA

October 23rd 2024

Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy

Autologous cell and gene therapies show promise but face barriers such as high costs, limited access, and payer concerns over long-term effectiveness.

REGENXBIO’s ABBV-RGX-314 Reduces Need for AntiVEGF Injections After Application in Fellow Eyes of Patients With Wet AMD

Joshua M. Hare, MD, the cofounder and chief science officer of Longeveron, discussed working to show potential benefits in a follow-up phase 3 trial.

Promising Data on Lomecel-B for Alzheimer Disease

The data comes from a phase 2 substudy (NCT03999801) that treated the fellow eyes of patients who had previously been treated with ABBV-RGX-314.

MeiraGTx’s Parkinson Disease Gene Therapy AAV-GAD Improves Motor Scores and Patient-Reported Quality of Life in Sham-Controlled Study

Joshua M. Hare, MD, the cofounder and chief science officer of Longeveron, discussed updated data from the phase 2a CLEAR MIND study.

Using Programmable Genomic Integration to Make Edits Big and Small

For the patients treated at the high dose, an average improvement of 18 points from baseline was observed in UPDRS Part 3 “off” medication score at 26 weeks posttreatment.

John Finn, PhD;Noah Stansfield